ATE355299T1 - Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung - Google Patents

Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung

Info

Publication number
ATE355299T1
ATE355299T1 AT96922458T AT96922458T ATE355299T1 AT E355299 T1 ATE355299 T1 AT E355299T1 AT 96922458 T AT96922458 T AT 96922458T AT 96922458 T AT96922458 T AT 96922458T AT E355299 T1 ATE355299 T1 AT E355299T1
Authority
AT
Austria
Prior art keywords
hif
inducible
factor
hypoxaemia
application
Prior art date
Application number
AT96922458T
Other languages
German (de)
English (en)
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE355299T1 publication Critical patent/ATE355299T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96922458T 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung ATE355299T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1

Publications (1)

Publication Number Publication Date
ATE355299T1 true ATE355299T1 (de) 2006-03-15

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922458T ATE355299T1 (de) 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung

Country Status (9)

Country Link
US (3) US5882914A (enExample)
EP (2) EP1806357A1 (enExample)
JP (2) JPH11507541A (enExample)
AT (1) ATE355299T1 (enExample)
AU (1) AU704384B2 (enExample)
CA (1) CA2222279C (enExample)
DE (1) DE69636936T2 (enExample)
IL (1) IL118581A (enExample)
WO (1) WO1996039426A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
WO1999009046A1 (en) 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes
AU757930B2 (en) 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
AU749467B2 (en) * 1997-12-04 2002-06-27 Genzyme Corporation Compositions and methods for inducing gene expression
WO1999048916A2 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
CA2341518A1 (en) * 1998-08-27 2000-03-09 Quark Biotech, Inc. Hypoxia regulated genes
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
WO2001023426A2 (en) * 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
CN1425075A (zh) * 2000-02-22 2003-06-18 牛津生物医学（英国）有限公司 差异表达筛选方法
AU2001290179B2 (en) * 2000-08-07 2007-07-12 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
WO2002094862A2 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
DE60232443D1 (de) * 2001-06-05 2009-07-09 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
ES2649817T3 (es) * 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
CA2482904A1 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
KR20120038546A (ko) * 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050014264A1 (en) * 2002-12-11 2005-01-20 University Of Massachusetts Method of introducing siRNA into adipocytes
WO2004066949A2 (en) 2003-01-28 2004-08-12 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
ES2333794T3 (es) * 2003-01-31 2010-03-01 Rexahn Pharmaceuticals, Inc. Oligonucleotidos que inhiben la expresion de hif-1.
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
ES2596885T3 (es) 2006-06-07 2017-01-12 Genzyme Corporation Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
SI2497500T1 (sl) 2006-10-03 2017-01-31 Genzyme Corporation Genska terapija za spinalno mišično atrofijo
NZ598092A (en) * 2008-02-14 2012-07-27 Lincoln University Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
MX2011005851A (es) 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
RS67077B1 (sr) 2009-05-02 2025-08-29 Genzyme Corp Genska terapija za neurodegenerativne poremećaje
EP4219708A3 (en) 2009-07-17 2023-10-11 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CA2895791A1 (en) * 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
JP6836400B2 (ja) 2014-03-28 2021-03-03 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 乳がんおよび卵巣がんワクチン
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059131A1 (en) * 1989-06-23 1990-12-24 Ming-Shi Chang Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP0833840B1 (en) 2007-02-28
WO1996039426A1 (en) 1996-12-12
IL118581A0 (en) 1996-10-16
CA2222279A1 (en) 1996-12-12
AU704384B2 (en) 1999-04-22
JPH11507541A (ja) 1999-07-06
US5882914A (en) 1999-03-16
EP0833840A1 (en) 1998-04-08
EP0833840A4 (en) 2001-12-19
JP2009077729A (ja) 2009-04-16
AU6332696A (en) 1996-12-24
US6020462A (en) 2000-02-01
IL118581A (en) 2000-01-31
EP1806357A1 (en) 2007-07-11
CA2222279C (en) 2011-02-01
DE69636936D1 (de) 2007-04-12
DE69636936T2 (de) 2007-10-31
US6222018B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ATE355299T1 (de) Faktor-1, induzierbar durch hypoxaemie, und verfahren zur anwendung
DE69403610D1 (de) Verfahren zur Herstellung von Ameisensäure und ihren Derivaten
AT362780B (de) Verfahren zur herstellung von neuen substituierten aminosaeuren bzw. deren estern und ihren salzen
DE69221765D1 (de) Verfahren zur Herstellung von Polybutadien
DE69534801T8 (de) Neues lysin decarboxylasegen und verfahren zur herstellung von l-lysin
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE141923T1 (de) Verfahren zur abtrennung von metallorganischen verbindungen und/oder metallcarbonylen aus ihren lösungen in organischen medien
DE68919246D1 (de) Verfahren zur Herstellung von Aminosäuren.
DE3888360D1 (de) Hochspannungsschalter und verfahren zur ansteuerung von verbrauchern mittels des hochspannungsschalters.
DE3680632D1 (de) Verfahren zur herstellung von kohlenstoffasern und diese kohlenstoffasern.
DE69508722D1 (de) Verfahren zur Herstellung von Carbonsäuren durch Oxydation der entsprechenden Alkane
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE69419238D1 (de) Polyimidvorläufer-Zusammensetzung, Polyimid-Zusammensetzung und Verfahren zur Herstellung dieser Polyimid-Zusammensetzung
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE69314779D1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATA95282A (de) Verfahren zur herstellung von neuen aromatischen carbonsaeuren und ihren salzen
ATE108174T1 (de) Verfahren zur herstellung von r(+)-aminocarnitin und s(-)-aminocarnitin.
DE59606111D1 (de) Verfahren zur Herstellung von Carbonsäuren durch Carbonylierung von Olefinen
DE69313297D1 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
DE69318642D1 (de) Verfahren zur Herstellung von Carbonester Verfahren zur Herstellung von Carbonester
DE69322358D1 (de) Automatisches Verfahren zur Herstellung von flexiblen Druckplatten, wobei diese mit ihren sensibilisierten Oberflächen nach oben verarbeitet werden, und Vorrichtung zur Ausführung des Verfahrens
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
DE3675623D1 (de) Verfahren zur fermentativen herstellung von l-aminosaeuren aus alpha-ketocarbonsaeuren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties